Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Abstract format and assignment number: Oral presentation 0772
Presenting author: A. Kerschbaumer (Austria)
Date: Saturday, 16th November 2024
This study analyzed placebo arms in psoriatic arthritis clinical trials, revealing that placebo response rates (ACR20) have increased over time, correlating with a shift in recruitment toward less affluent countries. This trend may result from limited access to healthcare in these regions, leading to higher regression to the mean.
The findings highlight the influence of geographic and socioeconomic factors on trial outcomes and call for consideration in trial design and interpretation.
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
Abstract format and assignment number: Poster 0548
Presenting author: D. Kiefer (Germany)
Date: Saturday, 16th November 2024
The study explores the impact of kinesiophobia, assessed by the Tampa scale, on patient-reported outcomes and mobility in axial spondyloarthritis (axSpA). Results show that higher kinesiophobia levels are associated with poorer outcomes, reduced performance in mobility tests, and lower quality of life. The findings suggest that addressing kinesiophobia could improve physical function and patient-reported experiences in axSpA management.
Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Abstract format and assignment number: Poster 0554
Presenting author: C. Merino (Spain)
Date: Saturday, 16th November 2024
The study found higher intestinal inflammation prevalence in radiographic axSpA (r-axSpA) than in non-radiographic axSpA (nr-axSpA), assessed via ileocolonoscopy performed in 287 patients. Inflammation was more common in patients with higher disease activity (ASDAS >2.1) and in HLA-B27-positive individuals. These findings suggest a stronger gut-joint axis involvement in r-axSpA, supporting stratified patient care and further investigation into shared inflammatory pathways.
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Abstract format and assignment number: Poster 0559
Presenting author: D. Benavent (Spain)
Date: Saturday, 16th November 2024
A study using the METEOR-SpA registry applied machine learning to predict disease flares in axial spondyloarthritis (axSpA) patients treated with b/tsDMARDs. Among 1,199 patients, 16.4% experienced flares within six months.
The best-performing model, constructed by reduced logistic regression, identified four predictors of flare within 6 months: lower ASDAS, history of enthesitis, number of previous flares, and longer treatment duration.
Investigating the Association Between Alcohol Consumption and Spinal Radiographic Progression in Axial Spondyloarthritis: A Longitudinal Cohort Analysis over a Period of 6 Years
Abstract format and assignment number: Oral presentation 0822
Presenting author: E. Gendron (Canada)
Date: Saturday, 16th November 2024
This study evaluated whether alcohol consumption influences spinal radiographic progression in axial spondyloarthritis (axSpA) over six years. Using data from 387 patients (769 radiographic intervals), researchers found that alcohol consumption was associated with increased odds of progression, particularly in males and those with radiographic axSpA (r-axSpA). The relationship was not mediated by inflammation (ASDAS), suggesting other mechanisms. Future studies should explore non-inflammatory pathways influencing structural damage.
Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
Abstract format and assignment number: Poster 1476
Presenting author: M. Hwang (USA)
Date: Sunday, 17th November 2024
Using N-of-1 trials analysed with Bayesian statistics, the study evaluated individual patient responses to NSAIDs, aiming to optimise treatment effectiveness and minimise side effects. No particular NSAID was globally chosen over the other NSAIDs but on a patient level, the preferred drug conferred a greater reduction in ASDAS compared to the others. This methodology supports tailored treatments by integrating patient-specific data into clinical decision-making.
Olivier Fakih
Olivier is a rheumatology fellow at the Department of Rheumatology of Besançon University Hospital in France.
His research interests include the epidemiology of inflammatory rheumatic diseases, in particular, mortality and comorbidities in spondyloarthritis. Olivier is a member of the French Society of Rheumatology and the society’s young rheumatologists section (REF).
He is a member of the EMEUNET Education Sub-Committee.